268 related articles for article (PubMed ID: 29679304)
1. Analytic Approaches for the Treatment of Hyperhomocysteinemia and Its Impact on Vascular Disease.
Kang SS; Rosenson RS
Cardiovasc Drugs Ther; 2018 Apr; 32(2):233-240. PubMed ID: 29679304
[TBL] [Abstract][Full Text] [Related]
2. Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification.
Selhub J; Jacques PF; Bostom AG; Wilson PW; Rosenberg IH
Public Health Rev; 2000; 28(1-4):117-45. PubMed ID: 11411265
[TBL] [Abstract][Full Text] [Related]
3. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.
Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M;
Clin Chem Lab Med; 2003 Nov; 41(11):1392-403. PubMed ID: 14656016
[TBL] [Abstract][Full Text] [Related]
4. Hyperhomocysteinemia: an additional cardiovascular risk factor.
Fanapour PC; Yug B; Kochar MS
WMJ; 1999 Dec; 98(8):51-4. PubMed ID: 10639897
[TBL] [Abstract][Full Text] [Related]
5. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
[TBL] [Abstract][Full Text] [Related]
6. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.
Clarke R; Armitage J
Semin Thromb Hemost; 2000; 26(3):341-8. PubMed ID: 11011852
[TBL] [Abstract][Full Text] [Related]
7. The folic acid metabolite L-5-methyltetrahydrofolate effectively reduces total serum homocysteine level in orthotopic liver transplant recipients: a double-blind placebo-controlled study.
Akoglu B; Schrott M; Bolouri H; Jaffari A; Kutschera E; Caspary WF; Faust D
Eur J Clin Nutr; 2008 Jun; 62(6):796-801. PubMed ID: 17522618
[TBL] [Abstract][Full Text] [Related]
8. [Hyperhomocysteinemia and cardiometabolic risk].
Vannucchi H; Melo SS
Arq Bras Endocrinol Metabol; 2009 Jul; 53(5):540-9. PubMed ID: 19768245
[TBL] [Abstract][Full Text] [Related]
9. [Risk factors for cardiovascular diseases: what is the role for homocysteine?].
Bendini MG; Lanza GA; Mazza A; Giordano A; Leggio M; Menichini G; De Cristofaro R; Moriconi E; Cozzari L; Farina SM; Giordano G
G Ital Cardiol (Rome); 2007 Mar; 8(3):148-60. PubMed ID: 17461357
[TBL] [Abstract][Full Text] [Related]
10. Cyclic supplementation of 5-MTHF is effective for the correction of hyperhomocysteinemia.
Ambrosino P; Lupoli R; Di Minno A; Nardo A; Marrone E; Lupoli V; Scaravilli A; Mitidieri E; Tufano A; Di Minno MN
Nutr Res; 2015 Jun; 35(6):489-95. PubMed ID: 25841618
[TBL] [Abstract][Full Text] [Related]
11.
Huang X; Qin X; Yang W; Liu L; Jiang C; Zhang X; Jiang S; Bao H; Su H; Li P; He M; Song Y; Zhao M; Yin D; Wang Y; Zhang Y; Li J; Yang R; Wu Y; Hong K; Wu Q; Chen Y; Sun N; Li X; Tang G; Wang B; Cai Y; Hou FF; Huo Y; Wang H; Wang X; Cheng X
Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):679-685. PubMed ID: 29371246
[TBL] [Abstract][Full Text] [Related]
12. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. A case-control study of patients with early-onset thrombotic events.
D'Angelo A; Coppola A; Madonna P; Fermo I; Pagano A; Mazzola G; Galli L; Cerbone AM
Thromb Haemost; 2000 Apr; 83(4):563-70. PubMed ID: 10780318
[TBL] [Abstract][Full Text] [Related]
13. Effect of low doses of 5-methyltetrahydrofolate and folic acid on plasma homocysteine in healthy subjects with or without the 677C-->T polymorphism of methylenetetrahydrofolate reductase.
Litynski P; Loehrer F; Linder L; Todesco L; Fowler B
Eur J Clin Invest; 2002 Sep; 32(9):662-8. PubMed ID: 12486865
[TBL] [Abstract][Full Text] [Related]
14. Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?
De Vriese AS; Verbeke F; Schrijvers BF; Lameire NH
Kidney Int; 2002 Apr; 61(4):1199-209. PubMed ID: 11918726
[TBL] [Abstract][Full Text] [Related]
15. Genetic modulation of homocysteinemia.
Rozen R
Semin Thromb Hemost; 2000; 26(3):255-61. PubMed ID: 11011843
[TBL] [Abstract][Full Text] [Related]
16. Homocysteine and cardiovascular disease: a review of the evidence.
Wierzbicki AS
Diab Vasc Dis Res; 2007 Jun; 4(2):143-50. PubMed ID: 17654449
[TBL] [Abstract][Full Text] [Related]
17. Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trial.
Mazza A; Cicero AF; Ramazzina E; Lenti S; Schiavon L; Casiglia E; Gussoni G
J Biol Regul Homeost Agents; 2016; 30(3):921-927. PubMed ID: 27655522
[TBL] [Abstract][Full Text] [Related]
18. Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency.
Schwahn BC; Chen Z; Laryea MD; Wendel U; Lussier-Cacan S; Genest J; Mar MH; Zeisel SH; Castro C; Garrow T; Rozen R
FASEB J; 2003 Mar; 17(3):512-4. PubMed ID: 12551843
[TBL] [Abstract][Full Text] [Related]
19. L-folic acid supplementation in healthy postmenopausal women: effect on homocysteine and glycolipid metabolism.
Villa P; Perri C; Suriano R; Cucinelli F; Panunzi S; Ranieri M; Mele C; Lanzone A
J Clin Endocrinol Metab; 2005 Aug; 90(8):4622-9. PubMed ID: 15899950
[TBL] [Abstract][Full Text] [Related]
20. Homocysteine, folate, and cardiovascular disease.
Ward M
Int J Vitam Nutr Res; 2001 May; 71(3):173-8. PubMed ID: 11582839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
